Insight Molecular Diagnostics (IMDX) Invested Capital (2020 - 2025)
Insight Molecular Diagnostics (IMDX) has disclosed Invested Capital for 6 consecutive years, with -$31.0 million as the latest value for Q4 2025.
- Quarterly Invested Capital fell 157.65% to -$31.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31.0 million through Dec 2025, down 157.65% year-over-year, with the annual reading at -$31.0 million for FY2025, 157.65% down from the prior year.
- Invested Capital hit -$31.0 million in Q4 2025 for Insight Molecular Diagnostics, down from -$8.1 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $114.4 million in Q2 2021 to a low of -$31.0 million in Q4 2025.
- Historically, Invested Capital has averaged $39.6 million across 5 years, with a median of $35.3 million in 2022.
- Biggest five-year swings in Invested Capital: skyrocketed 186.47% in 2021 and later plummeted 176.0% in 2025.
- Year by year, Invested Capital stood at $66.6 million in 2021, then plummeted by 48.35% to $34.4 million in 2022, then crashed by 33.78% to $22.8 million in 2023, then tumbled by 152.88% to -$12.0 million in 2024, then crashed by 157.65% to -$31.0 million in 2025.
- Business Quant data shows Invested Capital for IMDX at -$31.0 million in Q4 2025, -$8.1 million in Q3 2025, and $1.8 million in Q2 2025.